财务摘要 (未经审核)（港币千元）截至六月三十日止六个月2025年2024年收入122,775135,347毛利47,27748,767本公司所有者应占溢利8,17218,510毛利率39%36%每股基本盈利 (港仙)0.581.31香港，2025年8月28日 - (亚太商讯 via SeaPRwire.com) - 中国优质葡萄酒生产商王朝酒业集团有限公司（「王朝」或「集团」）（股份代号：00828）今日公布截至2025年6月30日止未经审核之中期业绩。2025年上半年，由于集团加强沿海地区干白酒市场的开拓力度，推出新的白葡萄酒及起泡葡萄酒产品，集团白葡萄酒产品的销售收入保持良好势态。但受中国宏观经济及消费市场波动的影响，集团产品（尤其是高端葡萄酒产品）销量下跌，以及由于推广及宣传开支增加，集团2025年上半年收入较2024年同期下跌9%至约1.23亿港元，本公司所有者应占溢利较2024年同期减少56%至约8.2百万港元，每股基本盈利约为每股0.58 港仙。期内由于产品组合优化，集团毛利率由去年同期的36%上升至39%。集团白葡萄酒产品的销售于期内为集团的主要收益贡献来源。红葡萄酒与白葡萄酒产品的销售收入分别占集团整体收入约41%及54%。期内，红葡萄酒产品和白葡萄酒产品的毛利率分别为38%及39%。本集团积极求新，聚焦「5+4+N产品战略」，其中「N」代表集团推出N项需求定制，不断开拓创新产品，以满足中国不同类型消费群体的多元化需求。于回顾期内，本集团继续推出新产品及进行产品升级，以更好地满足不同葡萄酒口味及不同消费能力的消费者，旨在激发品牌活力，并巩固王朝作为国产葡萄酒代表的品牌形象。本集团以「王朝」品牌产销超过100种葡萄酒产品，迎合中国葡萄酒市场大众市场分部不同消费者群的各项需求和喜好。于回顾期内，本集团推出中高端新品－王朝乙巳蛇年生肖纪念干红葡萄酒，与中国生肖文化相融合，引领「国潮风」，以年轻化的视觉语言呈现生肖文化，吸引潜在消费者。于本期间，本集团持续加强与酒业协会的合作，开展「龙行高校」等活动，进一步扩大品牌在年轻族群中的认知度与美誉度。基于其现有的优质产品，本集团继续推出新产品并推进产品升级。本集团于二零二五年三月在第112届全国糖酒商品交易会上推出天阳茶酒系列、王朝百馥VSOP白兰地等新品，以进一步完善其产品矩阵，为消费者提供多元的消费选择。该系列茶香葡萄酒突破传统葡萄酒的局限，以「茶酒融合」为核心理念，凭借独特的酿造工艺迅速获得市场目光。这款茶香葡萄酒以白酒为基调，融合茉莉花及普洱茶的芬芳，在传统的气泡酒领域中，创造出一种全新的东方韵味。在全国糖酒商品交易会期间，本集团亦举办品酒会，王朝天夏酒庄的新品凭借独特的风味和精湛的酿造工艺，赢得业界的好评。除致力于中国核心葡萄酒业务外，本集团亦将通过新设立的合资公司，拓展新的酒类饮料领域，如酱香型白酒、黄酒及特种黄酒－陈皮酒，以实现收入来源的多元化。王朝酱香型白酒产品，即「汉」、「唐」、「宋」、「明」，已于天津核心市场新推出并得到热烈回响，并将于下半年进一步战略推广至其他地区。酱香型白酒产品满足不同消费习惯的客户群体的需求，并为本集团业务作出贡献。未来，酱香型白酒产业的发展及扩张及客户群体水平的持久提升，必将有效推动王朝葡萄酒及相关产品销售的增长，从而提升我们的行业影响力及品牌知名度。对于黄酒项目，经规划后，正于二零二五年下半年在江苏建设一座储罐容量为3,000吨黄酒及特种黄酒－陈皮酒的生产厂房。于建设工程竣工后，本集团将能够生产特种黄酒－东台陈皮酒，让本集团可有效扩展产品品类，把握中国黄酒行业的发展机遇，实现酒业高质量发展的重大战略举措。电商销售方面，于回顾期内，本集团的电商团队于传统电商平台全面运营在线商店销售产品，例如京东商城、天猫商城及拼多多，以及通过兴趣电商平台（包括小红书app、快手app及抖音app）全面创新品牌、品类、业务体系、流程和模式。本集团的自主品牌传播使其可继续获得主流消费群体和圈子的关注，并提高本集团面向年轻消费者的产品的有效市场渗透率。同时，电商团队积极培养电商直播人才，以进一步扩大其销售渠道及建立新客户群。此外，于回顾期内，本集团在大型葡萄酒品鉴大赛中屡获殊荣。在多个奖项中，「王朝锦邑桶藏12年XO白兰地」荣获二零二五年国际葡萄酒与烈酒大赛（「IWSC」）中的银奖。该比赛被视为葡萄酒和烈酒质量的国际评价标准。王朝百馥VSOP白兰地、金王朝马瑟兰干红葡萄酒以及天阳茶酒系列亦于中国酒业协会举办的「二零二四年青酌奖」各类别评选中获奖。「王朝梦园白葡萄酒」亦以其卓越的酒质荣获二零二五年春季FIWA法国国际葡萄酒大奖赛中国区金奖。此外，「王朝传承系列－干红葡萄酒」于同一比赛中荣获金奖。该等葡萄酒因其酒香优雅、酒体顺滑和口感圆润从众多参赛作品中脱颖而出，并在比赛中获得奖项，向国家及世界展示了王朝葡萄酒的魅力和实力。王朝主席万守朋先生总结︰「展望二零二五年下半年，本集团将继续聚焦市场和消费者需求，并通过技术创新提升产品质量。同时，本集团将继续创新营销策略，激发品牌活力，进一步扩大王朝产品的市场份额，加强王朝品牌作为国产葡萄酒代表的形象，并为中国葡萄酒行业树立标杆，将王朝美酒风尚带给更多的中国消费者。本集团将继续通过产品品类及消费场景的创新，以及跨行业合作，积极开拓新的营销前景，以提升销量，藉此支持国家扩大内需及释放消费增长潜力的工作。」关于王朝酒业集团有限公司王朝酒业集团有限公司于2005年1月26日在香港联合交易所有限公司主板上市，股份代号00828。成立于1980年，王朝为中国优质葡萄酒生产商，主要生产及销售「王朝」商标的葡萄酒产品，是中国第一家中外合资的酿酒企业，主要股东包括天津食品集团有限公司及法国葡萄酒巨头人头马集团。集团产销葡萄酒产品系列超过100种，及引入进口葡萄酒产品，为国内各消费层提供高质素及物超所值的葡萄酒。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月28日 - (亚太商讯 via SeaPRwire.com) - 8月27日，澳优乳业股份有限公司（股份代号：1717.HK，以下简称"澳优"或"公司"）发布2025年上半年业绩公告。公告显示：2025年1-6月，澳优实现营业收入约人民币38.87亿元，同比增长5.6%；实现EBITDA（息税折旧及摊销前利润）约人民币3.98亿元，同比增长29.7%；归属于母公司权益持有人应占利润约人民币1.81亿元，同比增长24.1%，实现营收利润持续韧性双增长。公告表示，2025年上半年，面对复杂多变的全球经济形势及竞争加剧的中国婴配粉市场环境，澳优稳步推进"奶粉+营养品"全家营养战略，进一步打造产品力、品牌力、渠道力、数智力及组织力，在消费者的信任、社会各界的支持和全体澳优人的共同努力下，营收、利润继续保持双增长趋势，以坚韧不拔的毅力和稳健扎实的步伐迈向高质量发展新阶段。分版块看，澳优自有品牌奶粉业务实现整体营收约人民币28.26亿元。其中，羊奶粉业务实现收入18.65亿元，同比增长3.1%，"领头羊"地位持续稳固，尼尔森IQ数据显示截至6月底公司羊奶粉市场占有率同比提升2.8个百分点至30.4%；在2024年中国进口婴幼童羊奶粉市场销售量份额及销售额份额均高达84%，已连续7年在中国进口婴幼童羊奶粉市场份额超6成。【1】与此同时,弗若斯特沙利文经市场研究确认：2024年佳贝艾特羊奶粉销量与销售额全球第一。【2】牛奶粉业务实现收入约人民币9.61亿元,营养品业务实现收入同比增长7.0%，并成功拓展至海外市场。分区域看，2024年羊奶粉中国业务实现收入约人民币13.81亿元；羊奶粉国际业务实现收入约人民币4.83亿元，同比大幅增长65.7%，国际业务多点开花，实现爆发式增长，在公司自有品牌配方羊奶粉业务总收入的占比进一步提升至25.9%。公告显示，中东地区在2025上半年继续保持澳优海外最大销售市场的地位；北美地区收入同比提升逾138.7%，成为澳优海外市场第二大营收来源，独联体地区收入同比增长33.8%。澳优在公告中表示，羊奶粉业务海外市场在过去两年保持高双位数复合增长率的基础上，于上半年再攀高峰，实现同比增长65.7%；营养品业务战略布局全面起势，成为驱动公司发展的重要动力。数据来源：【1】尼尔森IQ进口婴幼童羊奶粉零售追踪数据；时间段：2018年-2024年，连续7个年度；渠道范围：上海、江苏、浙江、安徽、河南、广东、湖南、湖北、福建、江西、北京、天津、黑龙江、吉林、辽宁、山东、山西、河北、陕西、四川、重庆、贵州、云南、广西的城市母婴渠道。【2】弗若斯特沙利文Frost & Sullivan《全球羊奶粉市场独立研究报告》（2025年4月）。基于对全球羊奶粉市场的研究，对2024年全球范围内主要羊奶粉品牌的销量以及销售额进行研究分析后做出的确认，调研数据覆盖2024年1月至12月。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月28日 - (亚太商讯 via SeaPRwire.com) - 碧瑶绿色集团有限公司（「碧瑶」或「集团」；股份编号：01397.HK）欣然宣布截至2025年6月30日止六个月（「期内」）之未经审核之中期业绩。期内，集团收益约13.5亿港元，较去年增加约4.8%。整体毛利率由去年同期7.5%增加至9.8%，带动整体毛利增加约37.0%，至约1.3亿港元。期内溢利约为5千9百万港元，较去年同期增加约128.1%。业务回顾及展望清洁作为集团的核心业务，继续于期内录得增长，收益相比去年同期增加4.0%，至约10.8亿港元，占集团总收益约79.6%。清洁业务毛利率由去年同期6.4%增加至7.9%，带动毛利增加27.4%，至约8千5百万港元，主要由于集团与政府各部门及不同机构的新清洁服务合约所致。集团的清洁服务涵盖不同场景，包括为政府辖下街道、街市、康乐场地、医院及诊所提供清洁服务。其他清洁场地遍及各大学、大型展览中心、香港国际机场、屋苑及私人机构等众多不同场所。废物管理及回收方面，期内收益为约1.5亿港元，占集团总收益约10.7%。废物管理及回收业务的毛利率由去年同期12.9%，大幅增加至19.2%，拉动该业务毛利上升约46.6%，至约2千8百万港元，主要受惠于政府积极推动回收，大幅扩展包括厨余的回收点网络，便利市民参与并有效刺激收集量及绿色科技业务所带动。集团继续为政府辖下的五区提供废物收集服务，服务人口约160万。回收方面，集团作为政府环境保护署（「环保署」）服务承办商，为香港数千个回收点提供收集服务（包括塑胶、玻璃樽、金属、废纸及厨余）。集团于期内为公共场所及学校的回收箱，提供收集服务。此外，碧瑶亦为香港众多环保署辖下的「绿在区区」回收环保站、回收便利点、智能回收机及不同机构，提供回收服务。另外，碧瑶为政府于香港多区负责玻璃容器收集及处理，以及厨余收集，为市场领导者之一。绿色科技业务方面，集团赢得新合约，为政府供应新一代太阳能废物压缩箱。此创新产品设计具有自动感应投入口及指示灯，在密封式设计下加装通风、照明及除臭等装置。同时配备大数据平台及无线技术实时监控数据，有效追踪废物收集点的状态，策略地部署资源，优化运作效率，并加强对未来措施的规划。此外，太阳能废物压缩箱采用光伏板，依靠可再生能源，大大减低碳排放，可灵活配置于不同场景，适合没有垃圾收集站的偏远地区。此产品预计于年内陆续推出市场。集团把握智慧城市发展的契机，近年致力扩大智能回收的市场份额。目前碧瑶智能回收产品，例如：智能回收机、智能厨余回收机及智能磅等已遍及香港不同角落，包括各政府场地及学校、私人屋苑、商业大厦、主题乐园、大型展覧及体育场馆等。每日24小时为市民提供便捷的回收体验，并有助提升香港整体回收量。集团与怡和机器有限公司合作位于香港屯门环保园的生物炭工厂，已开始营运，通过热解技术将园林废料转化为高质量生物炭以作各种应用，从而达到「转废为材」的目的。园艺方面，客户涵盖大型私人住宅、政府处所、学校、商场、酒店、机场、香港房屋委员会、香港赛马会、香港科学园、香港大学、香港科技大学及岭南大学等。集团期内为启德体育园、香港国际机场、港深创新及科技园、微型公园及东涌西新发展区提供园艺工程。虫害管理方面，集团期内继续为黄大仙区及大埔区提供虫害管理服务。此外，集团分别为古物古迹办事处辖下29个古迹及华人庙宇委员会辖下24间庙宇，提供白蚁防治及监测服务。截至2025年6月30日，集团的手头合约约31.0亿港元，为日后迎来可观的收益。集团于报告期后成功中标政府海事处一份为期三年总值约1.5亿港元的「香港东部水域海上垃圾清理及处理服务」合约。此合约标志着碧瑶的服务版图，成功由陆地策略性拓展至海洋，为集团业务发展的重要里程碑，进一步巩固其在香港综合环境服务市场的领导地位。根据合约，碧瑶将自2025年10月1日起，于香港东部水域（包括但不限于维多利亚港、中环、上环、铜锣湾、尖沙咀、油麻地、长沙湾、筲箕湾、观塘、西贡、吐露港及大埔等地区）提供全面的海上清洁及船只生活垃圾收集服务。获得此合约，代表市场充份肯定碧瑶成立45年来的卓越表现。集团将其陆上废物管理的专业标准与营运效率无缝延伸至海上，致力守护香港珍贵的海洋生态环境，为市民及旅客呈现一个更洁净、更美丽的维多利亚港。近日集团成功中标环保署两份为期35个月总值港币约4千3百万港元的合约。自2025年9月起，集团将负责营运「绿在太和」及「绿在宝琳」回收便利点，以及与邻近大厦、机构及社区持份者合作，建立及营运固定及流动回收点进行收集，提供便利市民的社区回收支援，以及在社区推动和教育市民分类回收，强化市民回收习惯。此外，政府提交的《2025年促进循环再造及妥善处置产品（杂项修订）条例草案》于2025年7月23日获立法会通过，为生产者责任计划订立适用于不同产品的共同法律框架。在此框架下，政府计划于明年提交有关塑胶饮料容器及纸包饮品盒生产者责任计划。此计划鼓励市民将使用完的容器交回作循环再造，从而获取回赠，有助大大增加回收率。受益于该计划，预计将直接拉动碧瑶回收量，为集团多年来于回收服务建设的投资及竞争壁垒，提供吸引回报。政府正全速发展北部都会区，其中四个新发展区，包括古洞北╱粉岭北、洪水桥╱厦村、元朗南及新田科技城已进入施工阶段。政府已经在四个新发展区收回逾400公顷私人土地，完成平整80公顷土地并陆续将这些土地交付部门兴建道路铁路基建、公私营房屋、学校、公众街市、生态保育，以至发展创科产业，相信为集团多个核心业务带来契机。展望未来，集团在致力提高各核心业务的市场份额的同时，积极于香港及以外地区扩张。同时因应公司的发展，适时寻找潜在的并购、合营、或新业务项目，加速未来业务增长，为股东缔造可观及长远回报。有关集团2025年度中期业绩公告详情，请浏览以下网址：https://www.baguio.com.hk/zh-hant/investor/notices/碧瑶绿色集团简介碧瑶绿色集团（股份代号：01397.HK）成立于 1980 年，为香港最大的综合环境管理方案供应商之一，提供环卫保洁、资源回收、循环再造、废物管理、绿色科技、绿色产品、园艺绿化工程及害虫防治等。集团应用最新科技，提供创新环境解决方案，为不同领域的客户提供服务，包括政府部门、各大机构及跨国企业。集团努力不懈地提升环境、社会及管治(ESG)的表现，以推进集团的可持续发展，为了更绿的明天，实现将香港推动成为更清洁、更绿色、更健康城市的愿景。 Copyright 2025 亚太商讯 via SeaPRwire.com.

- 华堂宁(R)销量同比增长108%，净销售额同比增长112%。医保覆盖持续扩大，二级和三级医院处方量显著增加，全面自主商业化成效显著。- 与拜耳终止独家推广服务协议后，确认一次性递延收入人民币12.435亿元，实现上半年盈利11.839亿元，公司在业绩期内首次实现盈利。- 在中国开展涉及80个中心和2000名2型糖尿病患者的真实世界研究，进一步证明多格列艾汀的广泛适用性和安全性。- 多格列艾汀75mg（商品名：MYHOMSIS(R)，華領片TM）在香港递交注册申请，加速布局大中华区及东南亚市场。- 毛利率显著提升，生产规模与运营效率持续优化。上海，2025年8月28日 - (亚太商讯 via SeaPRwire.com) - 华领医药（"公司"，香港联交所股份代号：2552）宣布公司及其附属公司截至2025年6月30日止六个月（"报告期"）未经审核的综合业绩，以及公司上半年业务进展与未来展望。报告期内，公司核心产品华堂宁(R)（多格列艾汀片）商业化加速，自主运营能力显著提升，研发进展顺利推进，财务表现实现突破性成长，为长期可持续发展奠定了坚实基础。华领医药创始人兼首席执行官陈力博士表示："2025 年上半年是华领医药转型发展的关键阶段。全面接管华堂宁(R)商业化后，公司凭借自主搭建的销售团队，实现了销量与收入的翻倍增长，印证了新的商业模式的有效性。我们还在中国香港递交了新药上市申请，为多格列艾汀从中国走向东南亚乃至全球市场奠定了基础。同时，多格列艾汀在真实世界研究中持续展现出广泛的治疗潜力，也在基础研究中发现了糖尿病缓解、认知改善、血脂改善和增肌等方面的新证据，进一步巩固了华领医药在GKA研发和治疗领域的全球领先地位。未来，华领医药将继续深耕糖尿病和整个代谢疾病领域，通过创新研发与市场拓展的双轮驱动，让中国原创新药惠及更多全球患者。"业务亮点与运营进展商业化转型成效显著，销售与利润双增长- 2025年1月1日起，公司终止与拜耳的独家推广服务协议，全面接管华堂宁(R)在中国的商业化运营。报告期内，在与2024年同期的单价保持一致的情况下，华堂宁(R)销量达176.4万盒，同比增长108%；净销售额达2.174亿元，同比增长112%。凭借强劲的商业执行力和不断提升的运营效率，公司迈向盈利。华领医药已顺利过渡到全面自主商业化阶段，也印证了日益增长的市场需求和自主销售团队的高效执行力。- 2024年被纳入中国国家医保药品目录(NRDL)后，2025年华堂宁(R)继续受益于广泛的医保覆盖，二级和三级医院的处方量显著增加，有助于提高患者的可及性和长期使用率。- 由于生产规模扩大和成本效率的提升，公司毛利率提升至54.2%，高于去年同期的46.5%。- 在销售额同比增长112%的情况下，报告期内公司销售费用为6420万元，与去年同期相比仅增长5%，报告期内销售费用约占总收入的29.5%，显著低于去年同期的59.5%。这是因为，2025年上半年销售费用构成与2024年同期相比发生了显著变化：由公司在中国承担华堂宁(R)的独家商业化责任而直接产生销售费用，而无需再向原商业化合作伙伴支付推广费用。这反映出公司显著的盈利向好趋势，也表明了公司的业务战略，即通过控制与华堂宁(R)商业化直接相关的销售费用，以及最大限度地提高生产效率，来优化盈利能力。- 与拜耳终止独家推广服务协议后，公司确认一次性递延收入12.435亿元，向自主驱动增长转型。华领医药首次实现半年税前利润11.839亿元，这是华领医药迈向可持续盈利的关键里程碑。- 截至2025年6月30日，现金余额为10.228亿元，为公司未来的研发和商业化举措奠定了坚实基础。临床研究持续深入，新证据支撑治疗潜力- 公司正在推进多项上市后研究，以评估多格列艾汀在不同患者群体中的长期安全性和有效性，包括单药治疗以及与其它已经获批的热门降糖药，如GLP-1受体激动剂、胰岛素、DPP-4抑制剂和SGLT-2抑制剂的联合用药。这些研究正在为血糖控制、认知改善和糖尿病缓解潜力等提供新的临床依据。- 公司正在开展多格列艾汀上市后真实世界研究（BLOOM），在全国80家中心纳入2000例2型糖尿病患者，目前已完成1000余例患者的1年随访。在真实世界环境中，BLOOM研究进一步证明了多格列艾汀的广泛适用性和安全性。在临床用药中，接受多格列艾汀治疗的患者往往存在多种合并症，包括各种心血管和肾脏疾病等，并且正在接受多种伴随药物治疗。除二甲双胍外，超过60%的患者在使用多格列艾汀的同时，还联合使用了SGLT-2抑制剂、胰岛素、GLP-1受体激动剂或DPP-4抑制剂等其它降糖药。无论是单药治疗还是联合用药，多格列艾汀普遍表现出良好的耐受性，安全性特征也与先前的临床研究数据保持一致。- 在2025年美国糖尿病协会（ADA）科学年会上，公司公布了多格列艾汀的新研究数据，进一步阐明其作为疾病修饰疗法的作用机制，关于多格列艾汀作为GKA药物的新作用机制的相关成果已发表于《糖尿病》（Diabetes）杂志上。研发管线与未来展望- 公司已在中国香港提交多格列艾汀75mg（商品名：華領片TM，MYHOMSIS(R)）的注册申请，旨在扩大在大中华区和东南亚的业务版图。- 公司正在通过开发二甲双胍和多格列艾汀的固定复方制剂拓展产品管线，用于服用高剂量二甲双胍（>每日1500mg）仍无法控制血糖的患者，此前的DAWN临床研究显示，多格列艾汀联合二甲双胍用药可使患者的糖化血红蛋白（HbA1c）降低超过1%，餐后血糖降低超过5mmol/L，低血糖发生率仅为0.8%。该血糖控制水平表明，多格列艾汀-二甲双胍固定剂量复方制剂作为口服降糖药具有强大的潜在需求。2025年8月，公司已完成IND前资料提交，预计于2026 年初启动生物等效性（BE）研究。- 通过收集真实世界证据以及在动物模型中开展概念验证研究，公司正在推进多格列艾汀与GLP-1受体激动剂、DPP-4制剂和SGLT-2抑制剂的联合用药。多格列艾汀与这些药物之间的协同作用有望将其适应症扩展到肥胖症、代谢相关脂肪性肝炎（MASH）等其它代谢紊乱疾病领域。- 公司将继续加强与国际领先的研究机构的合作。由华领医药支持的一项研究者发起的I 期临床研究正在宾夕法尼亚大学进行，旨在评估多格列艾汀在囊性纤维化相关糖尿病（CFRD）患者中的疗效和安全性，该试验已获得美国食品药品监督管理局（FDA）的批准。- 公司将继续致力于开发糖尿病预防、代谢紊乱相关神经退行性疾病领域的治疗机遇，最终找到一种新的方法来延长人类的健康寿命。- 公司将继续投资于数字技术平台，以在各个职能部门之间创造协同效应，并利用人工智能技术提升品牌机遇。- 公司将继续自主推进多格列艾汀和第二代GKA的研发，并与学术和战略合作伙伴共同开展相关工作。公司正在推进多格列艾汀在香港的注册，并继续在东南亚和"一带一路"国家寻求合作伙伴。基于美国I期单剂量递增研究的初步成功，公司计划于2025年底或2026年初启动多剂量递增I期研究，从而继续推动第二代GKA在全球市场的业务发展。财务摘要截至2025年6月30日- 公司银行结余及现金约人民币10.228亿元- 总营收约2.174 亿元，同比增长112%，华堂宁(R)销量达176.4万盒，同比增长108%- 毛利约1.178亿元，同比增长147%，毛利率约54.2%，同比增长7.7个百分点- 其他收入约12.546亿元，其中拜耳一次性递延收入为12.435亿元- 总开支约1.871亿元，其中研发开支约6580万元- 税前利润约11.839亿元，同比增长932%前瞻性声明本文包含有关华领医药以及产品未来预期、计划和前景的陈述。该等前瞻性陈述仅与本文作出该陈述当日的事件或资料有关，可能因未来发展而出现变动。除法律规定外，于作出前瞻性陈述当日之后，无论是否出现新资料、未来事件或其他情况，我们并无责任更新或公开修改任何前瞻性陈述及预料之外的事件。请仔细阅读本文并理解，由于各种风险、不确定性或其他法定要求我们的实际未来业绩或表现可能与预期有重大差异。关于华领华领医药（"本公司"）是一家总部位于中国上海的创新药物研发和商业化公司，在美国、中国香港设立了公司。华领医药专注于未被满足的医疗需求，为全球患者开发全新疗法。华领医药汇聚全球医药行业高素质人才，融合全球创新技术，依托全球优势资源，研究开发突破性的技术和产品，引领全球糖尿病医疗创新。公司核心产品华堂宁(R)（多格列艾汀片）以葡萄糖传感器葡萄糖激酶为靶点，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖稳态失调。2022年9月30日，华堂宁(R)已获得中国国家药品监督管理局（NMPA）的上市批准，用于单独用药或者与二甲双胍联合用药，治疗成人2型糖尿病。对于肾功能不全患者，无需调整剂量，是一款可用于肾功能损伤的2型糖尿病患者的口服降糖药物。详情垂询华领医药网址：www.huamedicine.com投资者电邮：ir@huamedicine.com媒体电邮：pr@huamedicine.com新闻免责声明本材料，如为上下文论述的准确性和完整性，提及在中国上市的产品相关信息的，特别是标识或要求，应遵循中国监管机构批准的相关文件。另外，相关信息不应被解读为对任何药物或者诊疗方案的推荐或者宣传，亦不应替代任何医疗卫生专业人士的医疗建议，涉及医疗的相关事宜务必咨询医疗卫生专业人士。 Copyright 2025 亚太商讯 via SeaPRwire.com.

香港，2025年8月28日 - (亚太商讯 via SeaPRwire.com) - 2025年8月，北京--首程控股有限公司（0697.HK，以下简称"首程控股"）、北京首程机器人科技产业有限公司（以下简称"首程机器人"）、阿尔特汽车技术股份有限公司（300825.SZ，以下简称"阿尔特"）、北京阿尔瑞特智能机器人科技有限公司（以下简称"阿尔瑞特"）正式签署战略合作框架协议。四方将充分发挥各自优势，围绕机器人产业的技术创新、应用落地、产业链协同与人才培养，展开全方位合作，推动"机器人+汽车"应用新业态加速发展。一、产业背景：机器人进入应用落地加速期当前，全球机器人产业正处于高速发展阶段，国家战略和政策密集出台。8月26日，国务院正式发布《国务院关于深入实施"人工智能+"行动的意见》（国发〔2025〕11号），明确提出要推动人工智能与经济社会各行业各领域的广泛深度融合，加快形成人机协同、跨界融合、共创分享的智能经济和智能社会新形态。在这一国家战略指引下，机器人产业正从"技术突破"迈向"应用落地"。汽车与机器人作为两个高度契合的产业，正逐渐呈现跨界融合趋势。此次首程控股与阿尔特集团的合作，将在政策东风与市场需求的双重驱动下，为机器人在研发、制造、交通和出行服务等关键环节的应用注入新动能。阿尔特是中国汽车设计领域的领军企业，也是A股市场唯一的独立汽车设计上市公司，具备整车研发设计与核心零部件制造的全流程服务能力，并践行"技术+供应链"的国际化战略。据公开信息，公司累计服务超80家客户，参与开发近500款车型，客户涵盖一汽、东风、北汽、吉利、新势力品牌与合资企业等主机厂类型。这意味着阿尔特在汽车产业链中拥有深厚的主机厂资源与交付能力。与此同时，阿尔特通过控股子公司--北京阿尔瑞特智能机器人科技有限公司，已正式开辟机器人新赛道。阿尔瑞特致力于打造一体化研发设计与仿真训练平台，能够为多场景机器人开发提供从仿真、测试到优化的全流程支撑；目前已启动轮式机器人、水下机器人、钻井机器人和宠物洗护机器人等多个研发项目，体现了其跨场景研发和产业协同的潜力。阿尔瑞特的加入，使本次合作不仅局限于传统汽车设计层面的协作，更在机器人研发、仿真与汽车产业化融合方面提供了重要支撑。与阿尔特及阿尔瑞特的合作，将帮助首程把机器人技术深度嵌入汽车产业链的核心环节，如整车制造、智能装配与产线测试，使机器人真正进入产线、加速产业应用。这一战略合作不只是一种技术对接，更是借助阿尔特在主机厂客户群体中的资源网络，将机器人场景从"隔壁展示"一步推向"生产车间"，连接研发验证与规模化交付的关键路径。二、合作重点：研发突破与应用落地并举在国务院"人工智能+"行动政策引领下，四方将立足"技术研发-产业应用-生态共建"全链条，协同推进产业创新，重点在以下方向开展合作，助力机器人与汽车深度融合：（一）技术创新与联合研发四方将联合建设机器人一体化研发与仿真平台，借鉴汽车行业的完整研发体系，重点在运动控制、结构优化、车规级零部件和规模化制造等关键环节实现突破。同时，依托NVIDIA Isaac/Omniverse技术，共同打造一体化仿真训练平台，不仅支持机器人在汽车研发、制造和测试中的应用模拟，还可开展智能驾驶车辆与物流机器人协同作业等跨场景模拟。双方还将建立数据与成果共享机制：首程控股提供来自交通、出行等运营环节的数据资源，阿尔特输出汽车工程和机器人研发经验，形成从仿真-研发-验证-产线应用的完整闭环。（二）优先采购与协同机制在研发设计、仿真训练、整机和零部件供应等环节，四方将实行优先采购机制，在同等条件下优先选择协议方为合作伙伴。首程控股与首程机器人重点提供产品推广、代理及配套服务；阿尔特与阿尔瑞特聚焦于技术研发、工程化验证和定制化整机开发。各方将协同推进机器人本体二次开发，确保机器人产品在汽车生产线、智能装配和产线检测等场景下实现最佳适配。通过分工协作，形成产品供给-技术创新-应用反馈的互补格局，加快成果转化，提升商业化效率。（三）人才培养依托首程、阿尔特及其合作伙伴的科研与产业平台，四方将联合开展技术攻关、仿真训练与应用试点，为科研人员和工程师提供跨行业、跨场景的实践环境。同时，定期举办技术研讨会和产业论坛，邀请行业专家和上下游企业参与，建立联合人才培养机制，打造一批兼具汽车工程背景与机器人产业化实践经验的青年科研人才，夯实长期发展的人才基础。（四）拓宽发展空间四方将深度对接国家"人工智能+"与机器人产业发展战略，重点推动"机器人+汽车"在研发、制造、测试和出行服务环节的规模化应用。在此基础上，合作还将逐步延展至智慧交通、智能制造、医疗健康、教育、公共服务等更广阔的领域，涵盖机器人及核心零部件的设计、研发、生产、测试和商业化服务。同时，结合资本与产业的联动，推动产业链上下游协同升级，最终形成从研发验证到规模化应用的全链条闭环，打造具有示范效应的"机器人+汽车"应用矩阵，实现互利共赢和长期价值创造。三、战略意义：打造机器人应用新标杆机器人产业的最大价值在于应用落地，而"机器人+汽车"正是最具潜力和爆发力的应用方向之一。从整车研发到智能制造，从交通调度到智慧出行，机器人将在汽车全产业链环节展现巨大价值。首程控股凭借资本平台、生态资源与产业基金优势，已投资宇树科技、银河通用、松延动力、星海图、加速进化等国内头部企业，具备前沿技术的整合能力；首程机器人则与上百家上下游优质企业建立合作，成为国内链接资源最全面的平台之一。阿尔特与阿尔瑞特则将汽车领域成熟的工程体系迁移至机器人研发与产业化。双方优势叠加，构建起"研发-迭代-应用-规模化"的完整路径。此次携手阿尔特，将进一步把首程的场景资源与产业生态，与阿尔特在整车研发、工程化能力与产业化经验深度结合。未来1-2年，合作将聚焦"机器人+汽车"的深度融合，率先在汽车研发、生产制造、智慧交通与出行服务等环节实现规模化应用示范，推动机器人从实验室走向产业化、规模化，加速形成具备示范效应的"机器人+汽车"应用矩阵。与此同时，合作也将放眼国际市场，推动中国方案走向全球，培育新质生产力，为股东创造长期价值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亚太商讯 via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Everbright Limited ("CEL" or "the Company", stock code: 165.HK) announced its Interim results for the six months ended 30 June 2025 ("the reporting period").Highlights of the 2025 Interim Results- Strong Growth: Total income reached HK$2,068 million, representing a significant increase compared with the same period last year;- Turning Around from Loss to Profit: During the reporting period, the Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company was HK$399 million, successfully turning around from a net loss;- Fundraising Increase: The total assets under management (AUM) of CEL's funds amounted to approximately HK$119.4 billion, with new fundraising amounting to approximately HK$2,741 million;- Successful Exits: The total exits from funds and principal investments amounted to HK$2.018 billionï¼›with a MOIC (multiple on invested capital) of approximately 2.78 times;- Cost Control and Efficiency Enhancement: Enhanced lean management led to a 10% year-on-year decrease in operating costs and a 38% year-on-year reduction in finance costs;- Adequate Liquidity: The Company had cash and cash equivalents of approximately HK$8.1 billion;- Steady Dividend: An interim dividend of HK$0.05 per share for 2025.In the first half of 2025, China's private equity industry entered a more stable stage of development. Leveraging its strengths as patient capital, CEL maintained strategic focus, seized market opportunities with precision, and promptly adjusted its fundraising, investment, management, and exit strategies. By consolidating its core businesses, gradually unlocking value potential, and significantly improving overall operational efficiency, the Company achieved a strong rebound in performance.During the reporting period, CEL realised total income of HK$2,068 million, representing a significant increase of HK$2,182 million from the same period last year. This was mainly due to a significant increase in investment income, which fully demonstrated the Company's sound investment vision and solid foundation in long-term investing. The Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company amounted to HK$399 million, successfully turning around from a net loss attributable to shareholders of HK$1,282 million in the same period last year, representing a significant improvement in performance.Meanwhile, the Company continued to strengthen its refined management, sustaining healthy and steady business development. During the reporting period, operating costs represented a year-on-year decrease of 10%, with proactive leverage reduction measures implemented. The gearing ratio decreased by 2% compared with the end of 2024, while finance costs fell 38% year-on-year, demonstrating significant results in cost control and efficiency improvement. As at the end of June 2025, the Company had cash and cash equivalents of approximately HK$8.1 billion, representing sufficient liquidity.By concentrating its resources and business focus on high-potential products, the Company further reinforced its core business. During the reporting period, with new fundraising amounting to approximately HK$2,741 million, the total AUM of CEL’s funds amounted to approximately HK$119.4 billion, managing 72 fund products and covering primary market funds, secondary market funds, and fund of funds. During the reporting period, the Company invested in a total of 9 projects and exited, fully or partially, from 46 project.Following the practice of sharing the Company's operating results with shareholders, the Board declared interim dividend of HK$0.05 per share for 2025 (2024 interim dividend: HK$0.05 per share).Business Highlights in the First Half of 2025Firstly, CEL Harnessed the Strengths of Group-Based Operations to Enhance Fundraising SynergyIn the first half of 2025, the Company successfully launched the Huaian Hongze Guangqi Fund and the Xiamen Marine High-Tech Industrial Development Fund, with a total scale of RMB2.5 billion. The Huaian Fund targets growth-stage projects in the areas of new energy, new materials, and intelligent manufacturing, with its first round of capital contribution completed in the first half of the year. The Xiamen Marine Fund is dedicated to incubating and transforming scientific and technological innovations in the marine sector, driving the high-quality development of the marine economy. At the same time, several other funds have been approved and are progressing smoothly, following the established plan.Secondly, CEL Strengthened Core Businesses to Drive Robust Recovery in PerformanceDuring the reporting period, the Company total exits from funds and principal investments amounted to HK$2.018 billion. This include the full exit from Xpeng Motors, DAPU Telecom, and Taboola, alongside partial exit from iSoftStone, Dekon Food and Agriculture, 4Paradigm, and other projects. With a MOIC (multiple on invested capital) of approximately 2.78 times, these exits significantly boosted the DPI of multiple funds, generating substantial returns for LPs. Several listed projects, including Circle, Dekon Food and Agriculture, and NetEase Cloud Music, delivered strong market performance in the first half of the year, making notable contribution to the Company's investment returns. In the first half of the year, secondary market funds expertly capitalised on structural opportunities, achieving impressive investment performance. Notably, the Everbright Convertible Bond Opportunity Fund ranked second among similar funds in Barclays' performance rankings.Thirdly, CEL Anchored Strategy Around Scientific and Technological Innovation, With a Particular Focus on Key Industry SectorsGuided by deep industrial insight and a forward-looking strategic vision, the Company accelerated its investment activity in the first half of the year. It targeted emerging strategic industries such as artificial intelligence, chips and semiconductors, and biomedicine, with a total investment of approximately HK$264 million by funds. We have nurtured and supported a number of technology leaders, including Yangtze Memory and Wuhan Xinxin (both prominent domestic memory chip producers), HengYi Biotech (a company engaged in the research and development of innovative drug for tumors and autoimmune diseases), J-Sensor (astrategic supplier of domestic industrial automation modules and core sensors for new energy vehicles), and Tec-Do (a service provider in the field of big data and BI), among others. These investments reflect our commitment to strengthening China’s science and technology enterprises. Meanwhile, CEL supported excellent sub-funds such as Jinyi Capital and Eastern Bell Capital through its FoF platforms. These FoF investments allow us to fully leverage the advantages of resource amplification, risk diversification, and diversified returns.Fourthly, CEL Optimise Business Management to Unlock Growth MomentumIn the first half of the year, the Company continued to optimise its financing structure and took full advantage of the domestic interest rate cut cycle, issuing RMB3 billion in the first tranche of its 2025 medium-term notes at a coupon rate of 2.09% per annum — the lowest coupon rate in the Company's bond issuance history. During the reporting period, the Company's overall financing cost declined by 133 basis points year-on-year to 3.14%, while its finance costs reduced by 38% year-on-year. Operating costs also recorded year-on-year decrease of 10%, underscoring the solid progress made in reducing costs and increasing efficiency. The Company continued to optimise its risk management framework. CEL advanced the classification of risk assets, reinforced dynamic valuation management, and established a risk monitoring and early warning system, thereby improving the effectiveness of risk prevention and control across the full business cycle.Fifthly, CLE Enhanced Public Services and Upgraded Commercial Consumption.CEL leveraged its industrial strengths to enhance the quality of its products and services, catering to the growing demand for consumer services among citizens. In the commercial consumption arena, EBA successfully launched 18 "IMIX Park" shopping centres across nine cities nationwide,managing approximately 2.6 million square metres in total. These centres created approximately 37,700 jobs, attracted approximately 121 million customer visits, and hosted more than 4,500 tenant merchants in the first half of 2025. During the reporting period, Phase I of the "Zhongguancun ART PARK IMIX Parks", a flagship consumption infrastructure and urban renewal project in Beijing, opened smoothly, significantly upgrading the consumer experience and giving a strong boost to domestic demand.Sixthly, Key Portfolio Companies Maintain Stable Growth with Strong ResilienceThe core business of China Aircraft Leasing Group Holdings Limited (CALC) progressed steadily with remarkable improvements in operating quality and efficiency. The net profit attributable to shareholders recorded a year-on-year increase. As of June 30, 2025, CALC’s fleet reached 181 aircraft, leased to 41 airlines across 22 countries and regions. Everbright Senior Healthcare has been seizing the development opportunities in China's healthcare industry. As of 30 June 2025, Everbright Senior Healthcare has 237 institutions of various types in 49 cities across the country, it managed more than 30,000 beds, with occupancy rates increasing by 1.77%. Meanwhile, Terminus continued to deepen the integration of AI technology across multiple industries, driving intelligent transformation and implementing localised AI applications and digital-intelligent solutions, while receiving multiple authoritative certifications.Seventhly, CEL Strengthened ESG Framework to Promote Sustainable DevelopmentDuring the reporting period, CEL continued to promote the construction of its ESG system. the Company maintained an "A" rating in the MSCI ESG Rating and received the "BEST ESG (S)" award from the Hong Kong Investor Relations Association (HKIRA). The Company earnestly fulfilled its role as a corporate citizen by leveraging its own capabilities, organizing and participating in 46 cultural and social welfare activities in the first half of the year, serving over ten thousand people, and upholding high standards in discharging its social responsibilities.In the first half of 2025, under the strong leadership of the Everbright Group, the guidance of the Board of Directors, and the collective efforts of all employees, the Company achieved significant improvements in operational efficiency and quality, with new drivers of growth continuing to strengthen, resulting in hard-won achievements. As China's economy continues to improve and policy support intensifies, the Chinese private equity industry will embark on a new journey of high-quality development. CEL will seize market opportunities, capitalise on the momentum, and lay a solid foundation for a strong start to the 15th Five-Year Plan. In the second half of the year, CEL will continue to adhere to the overall principle of seeking progress while maintaining stability, continue to focus on revenue growth and cost control, optimise operational management, seize opportunities in key business areas such as fundraising, investment, management, and exit, leverage the cross-border platform and the synergistic advantages of the group, cultivate long-term patient capital, and advance the "five major financial initiatives", through scientific strategic planning, professional investment teams, and rigorous risk management, and continuously create value for shareholders.China Everbright Limited, https://www.everbright.com/en [SHSE:601818][HKEX:00165][OTCPK:CEVIF][OTCPK:CEVIY] Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - FWD Group Holdings Limited (“FWD Group” or “FWD”) today announced its interim results for the six months ended 30 June 2025.- New business sales were up 38 per cent to US$1.246 billion compared to 2024 on an annualised premium equivalent (APE) basis. New business contractual service margin (CSM) of US$794 million, with year-on-year growth of 34 per cent.- Operating profit after tax was up 9 per cent to US$251 million with continued positive contributions from each of the company’s four geographic reporting segments: Hong Kong SAR & Macau SAR; Thailand & Cambodia; Japan; and Emerging Markets.- Net profit of US$47 million is a record interim result under IFRS 17.- Further improved financial flexibility with an upgrade to FWD Group's ratings - with its notional insurer financial strength rating now A2 - as announced by Moody's in July 2025. Maintained a strong capital position with a 283 per cent solvency ratio* and net underlying free surplus generation that more than doubled to US$417 million. Dividends of over US$500 million were received from the geographic reporting segments. - Comprehensive tangible equity up 8 per cent to US$8.15 billion, and Group embedded value up 8 per cent to US$6.38 billion, reflecting the value created for shareholders during the first half of 2025. The company subsequently completed its IPO - which raised HK$3,611 million (approximately US$466 million) in gross proceeds – and began trading on 7 July 2025 under the stock code 1828 on the Hong Kong Stock Exchange.- Completed the build-out of a high-net-worth (HNW) hub in Asia operating out of three jurisdictions – Hong Kong SAR, Singapore and Bermuda – serving the global high-end insurance market with diversified asset allocation, wealth management and legacy planning. A new FWD Private lounge located in a prime commercial district in Hong Kong is now fully operational.Huynh Thanh Phong, Group Chief Executive Officer and Executive Director of FWD Group, said, “We’re delighted to report record interim results under IFRS 17 in our first earnings as a publicly listed company. The outstanding growth in new business CSM demonstrates our ability to execute our customer-led strategy successfully across Asia in a sustainable and profitable way.“We intend to use the net proceeds of our recent IPO to further enhance our capital position and financial flexibility, which may involve reducing debt, in support of further growth and reach with customers, digital capabilities and channels,” added Huynh Thanh Phong.In Hong Kong SAR & Macau SAR, outstanding growth was posted in new business sales and new business CSM, reflecting ongoing broad-based demand from both local and Mainland Chinese visitor customers and the full activation of the FWD Private HNW business. The company continues to focus on its multi-channel distribution strategy alongside product innovation – such as its indexed universal life offering developed following recent regulatory guidance, as well as new cross-border Greater Bay Area medical services for eligible customers.The Thailand & Cambodia reporting segment new business indicators were partly impacted by the exit from underwriting new business in the Thailand corporate care segment in 2024. The business remains well positioned in Thailand to meet demand for protection, medical and pension products from an aging population. Its exclusive bancassurance partnership with Siam Commercial Bank maintained its number one market position. Similarly, the company’s agents and advisors retained a number two position in the annual Million Dollar Round Table (MDRT) rankings released in July 2025. The MDRT is a global independent association recognised as a standard of excellence in the life insurance and financial services industries.In Japan, the business reported solid new business results from its individual protection focused portfolio. The introduction of its first savings offering in July – a Japanese yen single premium annuity product – marked the company’s entry into the savings and retirement needs market. The Emerging Markets segment reported strong new business sales growth, despite industry headwinds and economic uncertainty in several markets. In Indonesia, BRI Life – a joint venture where FWD Group holds a strategic 44 per cent investment and collaborates with Bank BRI – was number one in bancassurance by new business sales. In the Philippines and Vietnam, the company’s agents and advisors ranked number two in the latest annual MDRT rankings. Six months ended/as at 31 Dec or 30 Jun^ US$ millions, except for percentages2025 2024Growth(year on year CER basis) Profitability Operating profit after tax2512239% Net profit/(loss)473nm CSM balance5,9965,17411% Growth New business sales (APE)1,24687638% New business CSM79457334% Value of new business50640421% Customer indicators Purchase customer emotion – good or great92%92%n/a Claims customer advocacy – net promoter score6364n/a Risk & Capital Net underlying free surplus generation417193115% Group local capital summation method coverratio*283% 260%n/a Value Group embedded value6,3805,5698% Comprehensive tangible equity8,1507,1628% Return on tangible equity17%15%n/a About FWD GroupFWD Group (1828.HK) is a pan-Asian life and health insurance business that serves approximately 34 million customers across 10 markets, including BRI Life in Indonesia. FWD’s customer-led and tech-enabled approach aims to deliver innovative propositions, easy-to-understand products and a simpler insurance experience. Established in 2013, the company operates in some of the fastest-growing insurance markets in the world with a vision of changing the way people feel about insurance. FWD Group is listed on the main board of the Hong Kong Stock Exchange under the stock code 1828. For more information, please visit www.fwd.comFor media inquiries, please contact: groupcommunications@fwd.comSource: FWD Group Holdings Limited^ The results are for the six months ended 30 June 2025 and are compared to the same period in 2024. CSM balance, Group LCSM cover ratio, group embedded value, comprehensive tangible equity and return on equity 2024 values are December 2024 balances/ratios and growth rates are shown accordingly. Growth rates are represented on a constant exchange rate (CER) basis. Except for operating profit/(loss) after tax (non-IFRS measure), net profit/(loss), CSM, and comprehensive tangible equity, all other numbers are unaudited. Operating profit after tax and net profit after tax represent the amounts attributable to equity holders of the company and are presented net of non-controlling interests. New business sales are calculated on an annualised premium equivalent (APE) basis, based on 100 percent annualised first year premiums and 10 percent single premiums. Return on tangible equity is calculated as operating profit after tax, divided by the average of the balances of tangible equity as of the beginning and end of such period. Tangible equity is calculated as adjusted total equity attributable to shareholders of the company, minus the intangible assets net of non-controlling interests.*Prescribed capital requirement (PCR) basis Copyright 2025 ACN Newswire via SeaPRwire.com.